CDK4 and cancer: NDNB1182 selectively targets Hsp90β, leading to reduced CDK4 levels, reactivation of endogenous retroviral elements, and subsequent innate immune stimulation, effectively converting immunologically “cold” tumors to “hot.” These inhibitors demonstrate a distinct mechanism that augments both innate and adaptive immunity without the detrimental effects observed with pan-inhibitors, presenting a promising approach to overcoming resistance mechanisms in cancer immunotherapy.